Oncology drug expenditure governance in an antineoplastic drug unit: comparative economic analysis 2023–2025 and the stratified recovery rate

Introduction: Direct hospital pharmaceutical expenditure in Italy grew by +6.0% in 2025. Antineoplastic Drug Units (ADUs) play a key governance role through AIFA registry management, managed entry agreement (MEA) recovery, and prescribing appropriateness monitoring. No standardized indicator distinguishes recoveries dependent on local activity from those determined nationally.Methods: Retrospective three-year comparative economic analysis, 2023-2025, at the ADU of a local health authority in southern Italy (~540,000 inhabitants). Expenditure, patient volumes, preparation counts, and recoveries were extracted from the AIFA registry platform and ADU management system. Recoveries were stratified into Tier 1 (national: AIFA MEA rebates, Innovative Drug Fund receipts) and Tier 2 (local: Law 648/96 recoveries, trial and compassionate use cost avoidance). Gross (all recoveries over net expenditure) and Local (Tier 2 over net expenditure) Recovery Rates were calculated.Results: Net expenditure grew +8.0% in 2023, +19.0% in 2024 and +3.86% in 2025, below the +6.0% national growth, despite a +19.2% increase in treated patients (3,341 vs 2,804) and +21.8% in preparations. Cost per patient decreased from €11,286 to €9,837 (−12.8%). Total recoveries were €5,261,136, €5,291,062, and €8,918,159. The Gross Recovery Rate was 19.8%, 16.7%, and 27.1%; the Local Recovery Rate was 6.7%, 4.7%, and 6.5%.Conclusions: The ADU governance model was associated with simultaneous expansion of patient access and reduction of per-patient cost. The stratified Recovery Rate separates recoveries dependent on local activity from those determined nationally, offering a transparent, reproducible indicator for benchmarking ADU governance across Italian NHS settings and European health systems with national MEA frameworks.

Authors

Publication Details

Journal
Global & Regional Health Technology Assessment
Published
2026-11-17
DOI
https://doi.org/10.33393/grhta.2026.3970
Primary Topic
Pharmaceutical Economics and Policy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Oncology drug expenditure governance in an antineoplastic drug unit: comparative economic analysis 2023–2025 and the stratified recovery rate

Vito Gregorio Colacicco, Alessandro Maggi, Salvatore Pisconti, Francesco Colasuonno et al.
3 links
Global & Regional Health Technology Assessment
Pharmaceutical Economics and Policy
article

Oncology drug expenditure governance in an antineoplastic drug unit: comparative economic analysis 2023–2025 and the stratified recovery rate

Vito Gregorio Colacicco, Alessandro Maggi, Salvatore Pisconti, Francesco Colasuonno, Tiziana Guarino, Antonio Ungaro, Filomena D'Amico, Loredana Brandi, Viviana Bruno
article en

Abstract

Introduction: Direct hospital pharmaceutical expenditure in Italy grew by +6.0% in 2025. Antineoplastic Drug Units (ADUs) play a key governance role through AIFA registry management, managed entry agreement (MEA) recovery, and prescribing appropriateness monitoring. No standardized indicator distinguishes recoveries dependent on local activity from those determined nationally.Methods: Retrospective three-year comparative economic analysis, 2023-2025, at the ADU of a local health authority in southern Italy (~540,000 inhabitants). Expenditure, patient volumes, preparation counts, and recoveries were extracted from the AIFA registry platform and ADU management system. Recoveries were stratified into Tier 1 (national: AIFA MEA rebates, Innovative Drug Fund receipts) and Tier 2 (local: Law 648/96 recoveries, trial and compassionate use cost avoidance). Gross (all recoveries over net expenditure) and Local (Tier 2 over net expenditure) Recovery Rates were calculated.Results: Net expenditure grew +8.0% in 2023, +19.0% in 2024 and +3.86% in 2025, below the +6.0% national growth, despite a +19.2% increase in treated patients (3,341 vs 2,804) and +21.8% in preparations. Cost per patient decreased from €11,286 to €9,837 (−12.8%). Total recoveries were €5,261,136, €5,291,062, and €8,918,159. The Gross Recovery Rate was 19.8%, 16.7%, and 27.1%; the Local Recovery Rate was 6.7%, 4.7%, and 6.5%.Conclusions: The ADU governance model was associated with simultaneous expansion of patient access and reduction of per-patient cost. The stratified Recovery Rate separates recoveries dependent on local activity from those determined nationally, offering a transparent, reproducible indicator for benchmarking ADU governance across Italian NHS settings and European health systems with national MEA frameworks.

Global & Regional Health Technology AssessmentVol. 13(1)
Good health and well-being
Pharmaceutical Economics and Policy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon